Thioredoxin-1, chemokine (C-X-C motif) ligand-9 and interferon-γ expression in the neoplastic cells and macrophages of Hodgkin lymphoma: clinicopathologic correlations and potential prognostic implications

References

• Stein H, Delsol G, Pileri S, et al. Classical Hodgkin lymphoma: introduction. In: Swerdlow SH, Campo E, Harris NL, editors. WHO classification of tumors of haematopoietic and lymphoid tissues. IARC: Lyon; 2008. p. 326–329.
   Google Scholar
• Broeckelman PJ, Angelopoulou MK, Vassilakopoulos TP. Prognostic factors in Hodgkin lymphoma. Semin Hematol. 2016;53:155–164.
   PubMed Web of Science ®Google Scholar
• Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl J Med. 2010;362:875–885.
   PubMed Web of Science ®Google Scholar
• Tan KL, Scott DW, Hong F, et al. Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood. 2012;120:3280–3287.
   PubMed Web of Science ®Google Scholar
• Sanchez-Espiridion B, Martin-Moreno AM, Montalban C, et al. Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin lymphoma. Haematol Hematol J. 2012;97:1080–1084.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Ristow K, Colgan JP, et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin’s lymphoma. Haematol Hematol J. 2012;97:262–269.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Ristow K, Habermann TM, et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma. Br J Haematol. 2012;157:321–330.
   PubMed Web of Science ®Google Scholar
• Koh YW, Kang HJ, Park C, et al. The ratio of the absolute lymphocyte count to the absolute monocyte count is associated with prognosis in Hodgkin’s lymphoma: correlation with tumor-associated macrophages. Oncologist. 2012;17:871–880.
   PubMed Web of Science ®Google Scholar
• Vassilakopoulos TP, Dimopoulou MN, Angelopoulou MK, et al. Prognostic implication of the absolute lymphocyte to absolute monocyte count ratio in patients with classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine or equivalent regimens. Oncologist. 2016;21:343–353.
   PubMed Web of Science ®Google Scholar
• Hartmann S, Tousseyn T, Doring C, et al. Macrophages in T cell/histiocyte rich large B cell lymphoma strongly express metal-binding proteins and show a bi-activated phenotype. Int J Cancer. 2013;133:2609–2618.
   PubMed Web of Science ®Google Scholar
• Li C, Thompson MA, Tamayo AT, et al. Over-expression of thioredoxin-1 mediates growth, survival, and chemoresistance and is a druggable target in diffuse large B-cell lymphoma. Oncotarget. 2012;3:314–326.
   PubMed Web of Science ®Google Scholar
• Gromer S, Urig S, Becker K. The thioredoxin system-from science to clinic. Med Res Rev. 2004;24:40–89.
   PubMed Web of Science ®Google Scholar
• Arner ES, Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem. 2000;267:6102–6109.
   PubMedGoogle Scholar
• Powis G, Kirkpatrick DL. Thioredoxin signaling as a target for cancer therapy. Curr Opin Pharmacol. 2007;7:392–397.
   PubMed Web of Science ®Google Scholar
• Baker AF, Koh MY, Williams RR, et al. Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer. Pancreas. 2008;36:178–186.
   PubMed Web of Science ®Google Scholar
• Welsh SJ, Bellamy WT, Briehl MM, et al. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res. 2002;62:5089–5095.
   PubMed Web of Science ®Google Scholar
• Tonissen KF, Di Trapani G. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy. Mol Nutr Food Res. 2009;53:87–103.
   PubMed Web of Science ®Google Scholar
• Dimtsas GS, Georgiadi EC, Karakitsos P, et al. Prognostic significance of immunohistochemical expression of the angiogenic molecules vascular endothelial growth factor-A, vascular endothelial growth factor receptor-1 and vascular endothelial growth factor receptor-2 in patients with classical Hodgkin lymphoma. Leuk Lymphoma. 2014;55:558–564.
   PubMed Web of Science ®Google Scholar
• Maggio E, van den Berg A, Diepstra A, et al. Chemokines, cytokines and their receptors in Hodgkin’s lymphoma cell lines and tissues. Ann Oncol. 2002;13(Suppl. 1):52–56.
   PubMed Web of Science ®Google Scholar
• Steidl C, Connors JM, Gascoyne R. Molecular pathogenesis of Hodgkin’s lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol. 2011;29:1812–1826.
   PubMed Web of Science ®Google Scholar
• Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, et al. Prognostic factors in advanced stage Hodgkin’s lymphoma: the significance of the number of involved anatomic sites. Eur J Haematol. 2001;67:279–288.
   PubMed Web of Science ®Google Scholar
• Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, et al. Combination chemotherapy plus low dose involved field radiation for early clinical stage Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys. 2004;59:765–781.
   PubMed Web of Science ®Google Scholar
• Vassilakopoulos TP, Nadali G, Angelopoulou MK, et al. The prognostic significance of beta(2)-microglobulin in patients with Hodgkin’s lymphoma. Haematologica. 2002;87:701–708.
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. N Engl J Med. 1998; 339:1506–1514.
   PubMed Web of Science ®Google Scholar
• Angelopoulou MK, Vassilakopoulos TP, Siakantaris MP, et al. EBVD combination chemotherapy plus low dose involved field radiation is a highly effective treatment modality for early stage Hodgkin’s disease. Leuk Lymphoma. 2000;37:131–143.
   PubMed Web of Science ®Google Scholar
• Marneridis A, Vassilakopoulos TP, Boltetsou E, et al. Immunohistochemical expression and prognostic significance of CCND3, MCM2 and MCM7 in Hodgkin lymphoma. Anticancer Res. 2011;31:3585–3194.
   PubMed Web of Science ®Google Scholar
• Georgiadi EC, Sachinis N, Dimtsas G, et al. Evaluation of apoptosis in classical Hodgkin’s lymphoma comparing different methods. J BUON. 2012;17:746–752.
   PubMed Web of Science ®Google Scholar
• Doussis-Anagnostopoulou IA, Vassilakopoulos TP, Thymara I, et al. Topoisomerase II alpha expression as an independent prognostic factor in Hodgkin’s lymphoma. Clin Cancer Res. 2008;14:1759–1766.
   PubMed Web of Science ®Google Scholar
• Korkolopoulou P, Thymara I, Kavantzas N, et al. Angiogenesis in Hodgkin’s lymphoma: a morphometric approach in 286 patients with prognostic implications. Leukemia. 2005;19:894–900.
   PubMed Web of Science ®Google Scholar
• Rassidakis GZ, Medeiros LJ, Vassilakopoulos TP, et al. BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Blood. 2002;100:3935–3941.
   PubMed Web of Science ®Google Scholar
• Herling M, Rassidakis GZ, Medeiros LJ, et al. Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin’s lymphoma: associations with presenting features, serum interleukin 10 levels, and clinical outcome. Clin Cancer Res. 2003;9:2114–2120.
   PubMed Web of Science ®Google Scholar
• Qi ZL, Han XQ, Hu J, et al. Comparison of three methods for the detection of Epstein-Barr virus in Hodgkin’s lymphoma in paraffin-embedded tissues. Mol Med Rep. 2013;7:89–92.
   PubMed Web of Science ®Google Scholar
• Gulley ML, Glaser SL, Craig FE, et al. Guidelines for interpreting EBER in situ hybridization and LMP1 immunohistochemical tests for detecting Epstein-Barr virus in Hodgkin lymphoma. Am J Clin Pathol. 2002;117:259–267.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481.
   Web of Science ®Google Scholar
• Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc A. 1972;135:185–206.
   Web of Science ®Google Scholar
• Cox DR. Regression models and life tables (with discussion). J R Stat Soc B. 1972;34:187–220.
   Google Scholar
• Teruja-Feldstein J, Jaffe ES, Burd PR, et al. Differential chemokine expression in tissues involved by Hodgkin’s disease: direct correlation of eotaxin expression and tissue eosinophilia. Blood. 1999;93:2463–2470.
   PubMed Web of Science ®Google Scholar
• Pasanen AK, Kuitunen H, Haapasaari KM, et al. Expression and prognostic evaluation of oxidative stress markers in an immunohistochemical study of B-cell derived lymphomas. Leuk Lymphoma. 2012;53:624–631.
   PubMed Web of Science ®Google Scholar
• Peroja P, Pasanen AK, Haapasaari KM, et al. Oxidative stress and redox state-regulating enzymes have prognostic relevance in diffuse large B-cell lymphoma. Exp Hematol Oncol. 2012;1:2–7.
   PubMedGoogle Scholar
• Hirota K, Murata M, Sachi Y, et al. Distinct roles of thioredoxin in the cytoplasm and in the nucleus. A two-step mechanism of redox regulation of transcription factor NF-kappaB. J Biol Chem. 1999;274:27891–27897.
   PubMed Web of Science ®Google Scholar
• Tome ME, Johnson DB, Rimsza LM, et al. A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis. Blood. 2005;106:3594–3601.
   PubMed Web of Science ®Google Scholar
• Kamper P, Ludvigsen M, Bendix K, et al. Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma. Blood. 2011;117:6638–6649.
   PubMed Web of Science ®Google Scholar
• Ludvigsen M, Kamper P, Sorensen BS, et al. Differential protein expression of peroxiredoxin-1 in classical Hodgkin lymphoma: a possible correlation to clinical behaviour. Hematol Oncol. 2015;33:253–255.
   PubMed Web of Science ®Google Scholar
• Teruya-Feldstein J, Tosato G, Jaffe ES. The role of chemokines in Hodgkin’s disease. Leuk Lymphoma. 2000;38:363–371.
   PubMed Web of Science ®Google Scholar
• Birgersdotter A, Baumforth KRN, Porwit A, et al. Inflammation and tissue repair markers distinguish the nodular sclerosis and mixed cellularity subtypes of classical Hodgkin’s lymphoma. Br J Cancer. 2009;101:1393–1401.
   PubMed Web of Science ®Google Scholar
• Chang KP, Wu CC, Fang KH, et al. Serum levels of chemokine (C-X-C motif) ligand 9 (CXCL9) are associated with tumor progression and treatment outcome in patients with oral cavity squamous cell carcinoma. Oral Oncol. 2013;49:802–807.
   PubMed Web of Science ®Google Scholar
• Dukers DF, Jaspars LH, Vos W, et al. Quantitative immunohistochemical analysis of cytokine profiles in Epstein-Barr virus-positive and -negative cases of Hodgkin’s disease. J Pathol. 2000;190:143–149.
   PubMed Web of Science ®Google Scholar